Skip to main content
Clinical Trials/IRCT20240515061805N1
IRCT20240515061805N1
Recruiting
Phase 2

Comparison of dexmedetomidine versus propofol intravenous sedation for electrochemotherapy of breast cancer skin lesion: double-blinded clinical trial

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Shahid Beheshti University of Medical Sciences
Enrollment
36
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Symptomatic metastatic skin lesions (like bleeding, exudation, smell or ulceration)
  • development of skin metastases, in which the symptoms mentioned can be expected
  • Patients who receive systemic treatment and have a good effect on their primary cancer, but their skin lesions do not respond to these treatments or are progressing
  • patients preferring electrochemistry
  • multiple skin lesions or a lesion larger than 1 cm
  • ASA group II, I, III
  • patients between 18 and 60 years old

Exclusion Criteria

  • Pregnancy and breastfeeding
  • Allergy to any of the drugs used in the study
  • hypertension
  • impaired liver and kidney function
  • Hereditary heart diseases
  • ischemic heart disease,
  • using beta blockers and sedative drugs
  • refusing to sign an informed consent form

Outcomes

Primary Outcomes

Not specified

Similar Trials